Literature DB >> 6752035

Limited protective effect of rough mutant antisera in murine Escherichia coli bacteremia.

G Peter, M Chernow, M H Keating, J C Ryff, S H Zinner.   

Abstract

Previous studies in mice have demonstrated differing immunoprophylactic activity of antisera against rough mutants of Enterobacteriaceae in the prevention of lethal gram-negative bacteremia. In this study, in which CF1 mice were made bacteremic with a serum-resistant Escherichia coli 06:K2:H1, the composite survival was significantly (p less than 0.001) enhanced by i. v. pre-treatment one to two hours before injection with either normal rabbit sera or antisera to the J5 mutant of E. coli 0111. The protective efficacy of these preimmune and hyperimmune sera did not differ significantly. Since considerable variability in the mortality of control mice occurred in the 25 separate experiments, the results of individual experiments were grouped retrospectively according to survival in the individual control groups and compared for evidence of possible differences in the efficacy of these two sera. With the exception of a statistically significant difference in the efficacy in one group receiving an LD75-95 inoculum, no such differences were noted. Thus, the variable effects of a rough mutant antiserum were not explained by differences in the relative virulence in the inoculum. This study confirms earlier observations by others that the protective efficacy of the anti-J5 antisera in infected mice does not differ appreciably from that of normal rabbit sera, provided the same donor rabbits are the source of both preimmune and hyperimmune sera.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6752035     DOI: 10.1007/bf01666916

Source DB:  PubMed          Journal:  Infection        ISSN: 0300-8126            Impact factor:   3.553


  14 in total

1.  Experimental gram-negative bacterial sepsis: reevaluation of the ability of rough mutant antisera to protect mice.

Authors:  S E Greisman; J B DuBuy; C L Woodward
Journal:  Proc Soc Exp Biol Med       Date:  1978-07

2.  Treatment of E. coli and klebsiella bacteremia in agranulocytic animals with antiserum to a UDP-gal epimerase-deficient mutant.

Authors:  E J Ziegler; H Douglas; J E Sherman; C E Davis; A I Braude
Journal:  J Immunol       Date:  1973-08       Impact factor: 5.422

Review 3.  Immunochemistry of O and R antigens of Salmonella and related Enterobacteriaceae.

Authors:  O Lüderitz; A M Staub; O Westphal
Journal:  Bacteriol Rev       Date:  1966-03

4.  A new method for the extraction of R lipopolysaccharides.

Authors:  C Galanos; O Lüderitz; O Westphal
Journal:  Eur J Biochem       Date:  1969-06

5.  Functional role of antibody against "core" glycolipid of Enterobacteriaceae.

Authors:  L S Young; P Stevens; J Ingram
Journal:  J Clin Invest       Date:  1975-10       Impact factor: 14.808

6.  Successful treatment of human gram-negative bacteremia with antiserum against endotoxin core.

Authors:  E J Ziegler; J A McCutchan; H Douglas; A I Braude
Journal:  Trans Assoc Am Physicians       Date:  1981

7.  Immunization with R mutants of S. Minnesota. I. Protection against challenge with heterologous gram-negative bacilli.

Authors:  W R McCabe
Journal:  J Immunol       Date:  1972-03       Impact factor: 5.422

8.  Relationship of structure to function in bacterial endotoxins: serologically cross-reactive components and their effect on protection of mice against some gram-negative infections.

Authors:  A K Ng; C L Chen; C M Chang; A Nowotny
Journal:  J Gen Microbiol       Date:  1976-05

9.  Immunization with R mutants of Salmonella minnesota. II. Serological response to lipid A and the lipopolysaccharide of Re mutants.

Authors:  M A Johns; S C Bruins; W R McCabe
Journal:  Infect Immun       Date:  1977-07       Impact factor: 3.441

10.  The properdin system and immunity. III. The zymosan assay of properdin.

Authors:  L PILLEMER; L BLUM; I H LEPOW; L WURZ; E W TODD
Journal:  J Exp Med       Date:  1956-01-01       Impact factor: 14.307

View more
  6 in total

Review 1.  Immunotherapeutic advances in the treatment of gram-negative bacterial sepsis.

Authors:  D L Dunn
Journal:  World J Surg       Date:  1987-04       Impact factor: 3.352

2.  Antiserum against Escherichia coli J5: a re-evaluation of its in vitro and in vivo activity against heterologous gram-negative bacteria.

Authors:  M Trautmann; H Hahn
Journal:  Infection       Date:  1985 May-Jun       Impact factor: 3.553

3.  Use of mucin and hemoglobin in experimental murine gram-negative bacteremia enhances the immunoprotective action of antibodies reactive with the lipopolysaccharide core region.

Authors:  B J Appelmelk; A M Verwey-van Vught; J J Maaskant; W F Schouten; L G Thijs; D M Maclaren
Journal:  Antonie Van Leeuwenhoek       Date:  1986       Impact factor: 2.271

4.  Carumonam enhances reactivity of Escherichia coli with mono- and polyclonal antisera to rough Escherichia coli J5.

Authors:  B P Overbeek; J F Schellekens; W Lippe; B A Dekker; J Verhoef
Journal:  J Clin Microbiol       Date:  1987-06       Impact factor: 5.948

5.  All accessible epitopes in the Salmonella lipopolysaccharide core are associated with branch residues.

Authors:  N A Nnalue
Journal:  Infect Immun       Date:  1999-02       Impact factor: 3.441

6.  Prophylaxis of Pseudomonas aeruginosa infections in leukopenic mice by a combination of active and passive immunization.

Authors:  D Martinez; L T Callahan
Journal:  Eur J Clin Microbiol       Date:  1985-04       Impact factor: 5.103

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.